World's First In-Utero Stem Cell Therapy for Fetal Spina Bifida Found Safe in Landmark Study
Original: First in-utero stem cell therapy for fetal spina bifida repair is safe: study View original →
A Breakthrough in Fetal Medicine
Researchers at UC Davis Health have achieved a historic milestone: the world's first in-utero stem cell therapy for spina bifida has proven safe in a Phase 1/2a clinical trial. Results published in The Lancet garnered over 240 upvotes on Hacker News and widespread attention from the medical community.
CuRe Trial Results
The CuRe Trial combined traditional fetal surgery with placenta-derived stem cells administered in utero. Key safety findings include:
- No adverse effects linked to stem cell treatment
- Zero infections, spinal fluid leaks, or abnormal tissue growth
- Complete wound healing in all surgeries
- MRI scans showed reversal of hindbrain herniation in all infants
- No patients required shunts for hydrocephalus before discharge
Why Spina Bifida Matters
Spina bifida is a congenital condition affecting approximately 1,500 to 2,000 U.S. children annually, caused by incomplete closure of the spinal canal during fetal development. While conventional fetal surgery has improved outcomes, many patients face long-term mobility challenges that this stem cell approach may help address.
What's Next
The trial is now enrolling up to 35 patients with follow-up evaluations through age 6. Principal Investigator Diana Farmer, MD, stated: "Putting stem cells into a growing fetus was a total unknown. We are excited to report great safety." This landmark result opens a promising new chapter in fetal medicine and regenerative therapy.
Related Articles
UC Davis Health researchers confirmed the safety of the world's first in-utero stem cell therapy for fetal spina bifida in a Phase 1 trial published in The Lancet. All patients showed zero adverse effects and successful outcomes.
Google Research says its March 12, 2026 rollout adds urban flash flood forecasts to Flood Hub with up to 24 hours of advance notice. The system is trained in part on Groundsource, a dataset built by using Gemini to extract structured flood events from public news reports.
Google Research says a prospective study with Beth Israel Deaconess Medical Center found AMIE could operate with zero safety stops, strong diagnostic performance, and improved patient trust under live physician oversight. Published on March 11, 2026, the work is an early real-world test of conversational diagnostic AI inside a primary care workflow.
Comments (0)
No comments yet. Be the first to comment!